

REGIOSELECTIVE TRANSFORMATION OF UNSYMMETRICAL BIS(*N*-NITROSOSULFONAMIDES)  
LEADING TO OPTICALLY ACTIVE CYCLIC IMINO ACID DERIVATIVES  
FROM L-LYSINE AND L-ORNITHINE

Masaaki IWATA\* and Hiroyoshi KUZUHARA

RIKEN (The Institute of Physical and Chemical Research),  
Wako, Saitama 351-01


Chiral cyclic imino acid derivatives were prepared from unsymmetrical bis(*N*-nitrososulfonamides) of diaminocarboxylic acids, L-lysine and L-ornithine, in good yields through kinetically controlled regioselective *N*-nitrososulfonamide-sulfonate rearrangement.

The finding of kinetically controlled bifunctionalization of symmetrical  $\alpha,\omega$ -bis(*N*-nitrososulfonamides)<sup>1)</sup> encouraged us to examine its feasibility for the stereospecific synthesis of L-pipecolic acid (4) and L-proline (8) from the corresponding *N*-nitrososulfonamides, 1 and 5, of diaminocarboxylic acids, L-lysine and L-ornithine. The designed route to the naturally occurring cyclic imino acids from open-chain amino acids would be achieved if the transformation occurs exclusively at one *N*-terminal remote from the asymmetric center.

When  $N^\alpha, N^\epsilon$ -dinitroso- $N^\alpha, N^\epsilon$ -ditosyl-L-lysine methyl ester (1) was heated at ca. 80 °C in benzene for 24 h, methyl 2-tosylamino-6-tosyloxycaproate (2) was obtained in 28% yield as main product. Treatment of 2 with  $K_2CO_3$  in *N,N*-dimethylformamide gave methyl *N*-tosyl-L-pipecolate (3) ( $[\alpha]_D -37.2^\circ$  (c 0.62, MeOH)) in 90% yield. Surprisingly, when  $N^\alpha, N^\delta$ -dinitroso- $N^\alpha, N^\delta$ -ditosyl-L-ornithine methyl ester (5) ( $[\alpha]_D +38.5^\circ$  (c 0.65,  $CHCl_3$ )) was heated as described above, *N*-tosyl-L-proline methyl ester (6) ( $[\alpha]_D -79.1^\circ$  (c 0.69, MeOH)) was directly obtained in 49% yield, accompanied by methyl 2-tosylamino-5-tosyloxyvalerate (7) (7%). These observations clearly indicate that the *N*-nitrososulfonamide-sulfonate rearrangement reaction occurs exclusively at  $\omega$ -*N*-nitrosotosylamino group attached to the methylene group. The direct formation of 6 could be explainable by the intramolecular pericyclic transition state (A) as proposed in the previous report.<sup>1)</sup> Further support for the intermediacy of the  $\delta$ -tosyloxy group instead of that in the  $\alpha$ -position was provided by the reaction of L-aspartate derivative (9). This gave optically inactive diethyl 2-*O*-tosylmalate (10) (26%), diethyl fumalate (11) (5%), and optically active denitrosated product (52%) ( $[\alpha]_D +33.3^\circ$  (c 1.56,  $CHCl_3$ )). Loss of optical activity of 10 indicates that the rearrangement at the chiral center results in complete racemization. Therefore, the direct formation of 6 should proceed

through intramolecular reaction of the  $\delta$ -tosylate group with  $\alpha$ -*N*-nitrososulfonamide *via* the transition state (A).

Preparations of L-pipecolic acid from L-lysine and L-proline from L-ornithine have been reported by use of a conventional method<sup>2)</sup> and the double Walden inversion method,<sup>3)</sup> respectively. The present approach is characterized by (i) short-cut synthesis of optically active useful intermediate **3** leading to expensive L-pipecolic acid from cheap L-lysine, (ii) direct intramolecular cyclization *via* the transition state (A) with retention of configuration, and (iii) kinetically controlled regioselective rearrangement of unsymmetrical bis(*N*-nitrososulfonamides). Optically active cyclic imino acid derivatives, **3** and **6**, will be useful intermediates in stereospecific synthesis of alkaloids and in general organic synthesis.



Scheme 1. a: i) HCl/MeOH, ii) TsCl/pyridine, iii) NaNO<sub>2</sub>/Ac<sub>2</sub>O/AcOH. b: K<sub>2</sub>CO<sub>3</sub>/DMF. c: i) HCl/EtOH, ii) TsCl/pyridine, iii) NaNO<sub>2</sub>/Ac<sub>2</sub>O/AcOH. The circles on the arrow denote rearrangement in benzene.

#### References

- 1) M. Iwata and H. Kuzuhara, *J. Chem. Soc., Chem. Commun.*, **1985**, 918.
- 2) T. Fujii and M. Miyoshi, *Bull. Chem. Soc. Jpn.*, **48**, 1341 (1975).
- 3) S. Ohshiro, K. Kuroda, and T. Fujita, *J. Pharm. Soc. Jpn.*, **87**, 1184 (1967).

(Received September 28, 1985)